| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Divisions of Pulmonary and Critical Care Medicine, Georgetown University Medical Center, Washington, DC
2 From the Oregon Health Sciences University, Portland
3 From the Winthrop University Hospital, Mineola, NY
4 From the Genentech, Inc, South San Francisco, Calif.
Study objective: To study the safety and efficacy of aerosolized recombinant human DNase I in the treatment of idiopathic bronchiectasis.
Design: Double-blind, randomized, placebo-controlled, multicenter study.
Populations: Three hundred forty-nine adult outpatients in stable condition with idiopathic bronchiectasis from 23 centers in North America, Great Britain, and Ireland.
Interventions and measurements: Study patients received aerosolized rhDNase or placebo twice daily for 24 weeks. Primary end points were incidence of pulmonary exacerbations and mean percent change in FEV1 from baseline over the treatment period.
Results: Pulmonary exacerbations were more frequent and FEV1 decline was greater in patients who received rhDNase compared with placebo during this 24-week trial.
Conclusions: rhDNase was ineffective and potentially harmful in this group of adult outpatients in stable condition with idiopathic bronchiectasis. This contrasts with previously published results that demonstrated efficacy of rhDNase in patients with cystic fibrosis bronchiectasis.
Key Words: bronchiectasis • therapy • COPD • expectorants
Submitted on July 16, 1997
Accepted on October 22, 1997
This article has been cited by other articles:
|
|
 |
|
  A. E. O'Donnell Bronchiectasis Chest, October 1, 2008; 134(4): 815 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Santamaria, S. Montella, L. Camera, C. Palumbo, L. Greco, and A. L. Boner Lung structure abnormalities, but normal lung function in pediatric bronchiectasis. Chest, August 1, 2006; 130(2): 480 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Rosen Chronic Cough Due to Bronchiectasis: ACCP Evidence-Based Clinical Practice Guidelines Chest, January 1, 2006; 129(1_suppl): 122S - 131S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. O'Riordan, L. B. Seischab, Q.-L. Ying, E. Colon-Carreras, B. Chughtari, L. B. Palmer, and S. R. Simon Antiprotease Function of Airway Secretions in Purulent Tracheobronchitis Chest, November 1, 2005; 128(5): 3167 - 3176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K W Tsang, K C Tan, P L Ho, G C Ooi, J C Ho, J Mak, G L Tipoe, C Ko, C Yan, W K Lam, et al. Inhaled fluticasone in bronchiectasis: a 12 month study Thorax, March 1, 2005; 60(3): 239 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Weiner, R. Bucki, and P. A. Janmey The Antimicrobial Activity of the Cathelicidin LL37 Is Inhibited by F-actin Bundles and Restored by Gelsolin Am. J. Respir. Cell Mol. Biol., June 1, 2003; 28(6): 738 - 745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Barker Bronchiectasis N. Engl. J. Med., May 2, 2002; 346(18): 1383 - 1393. [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. BARKER, L. COUCH, S. B. FIEL, M. H. GOTFRIED, J. ILOWITE, K. C. MEYER, A. O'DONNELL, S. A. SAHN, L. J. SMITH, J. O. STEWART, et al. Tobramycin Solution for Inhalation Reduces Sputum Pseudomonas aeruginosa Density in Bronchiectasis Am. J. Respir. Crit. Care Med., August 1, 2000; 162(2): 481 - 485. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J A. INNES DNase in cystic fibrosis: the challenge of assessing response and maximising benefit Thorax, December 1, 1998; 53(12): 1003 - 1004. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
